In focus
Latest feed
Eli Lilly's Retatrutide Triumphs in Key Diabetes Trial, Poised to Reshape Obesity Treatment Landscape
The Final Word: Navigating Pharma's Powerhouse and Gold's Gleam in Today's Markets
Why Barclays Still Sees Eli Lilly as the Undisputed Champion in the Exploding GLP-1 Arena, Even as Rivals Crowd In
A Fresh Look at Pharma Giants: Why Cramer Says J&J, Merck, and Amgen Still Offer Value
